Adaptyx Biosciences Secures $14M to Revolutionize Patient Monitoring with AI-Powered Skin Patches
A new generation of remote patient monitoring (RPM) is poised to deliver continuous health insights, thanks to a $14 million investment in Adaptyx Biosciences and its innovative bio-wearable skin patch.
Remote patient monitoring is rapidly transforming healthcare, leveraging digital technologies to collect, analyze, and transmit patient health data directly to medical professionals. Adaptyx Biosciences is at the forefront of this evolution, developing a skin patch capable of sampling biomarkers from interstitial fluid – the fluid surrounding cells – offering a less invasive alternative to traditional testing methods.
The recent funding will be used to scale production of these RPM skin patches and refine the translation of complex molecular data into clinically actionable insights. According to a company release, the device continuously monitors vital signs including electrolytes, small molecules, and hormones. This data is then fed into an artificial intelligence (AI) platform designed to interpret the details and provide practical guidance for both patients and clinicians.
This capability promises earlier detection of health issues, allowing for proactive intervention before conditions escalate. Currently, the majority of specialized RPM focuses on cardiovascular health and diabetes management, but Adaptyx aims to expand the application of its technology. “The goal is to provide continuous monitoring, not just snapshots of health like those provided by traditional in vitro diagnostics (IVD) tests,” one analyst noted. The skin patch is being specifically designed to monitor cardiac biomarkers and provide detailed hormone and metabolite profiling, possibly impacting individuals with metabolic disorders and complementing fertility care.
The potential of RPM devices, such as the Adaptyx skin patch, is substantially amplified when integrated with traditional IVD tests. For example, the patch could be utilized to monitor for infectious diseases like chlamydia and HIV, and even coupled with companion diagnostic treatments in cancer care. This offers patients a discreet and comfortable way to monitor essential health information outside of a clinical setting, receiving updates remotely from their healthcare providers.Furthermore, RPM allows healthcare professionals to monitor multiple patients together, leading to increased efficiency, improved patient care, and reduced hospital readmissions.
Expanding the scope of RPM to encompass a wider range of health areas promises to create a more seamless connection between patients and their healthcare teams, ensuring timely follow-up care when needed. As an example, by tracking inflammatory factors, physicians can quickly assess a patient’s response to infection treatment.By combining minimally invasive RPM with AI-driven analytics, Adaptyx Biosciences’ skin patch aims to facilitate earlier detection of clinical deterioration, more personalized treatment plans, and a more efficient use of clinician time. RPM devices like this skin patch could also address a critical challenge in healthcare: the “data deficit,” by keeping patients connected to care between appointments and enabling interventions that prevent complications.
If successfully scaled and integrated into existing clinical workflows, this technology has the potential to revolutionize healthcare delivery, bridging the gap between episodic IVD testing and proactive, continuous health management.
Why,Who,What,and How did it end?
Why: Adaptyx Biosciences secured $14 million in funding to address the need for continuous,proactive health monitoring and to overcome the limitations of traditional,episodic diagnostic testing. The goal is to provide more personalized and efficient healthcare.
Who: Adaptyx Biosciences, a company developing bio-wearable skin patches, received a $14 million investment. The investment involved unspecified investors and will impact patients, clinicians, and the broader healthcare industry.
What: Adaptyx Biosciences is developing an AI-powered skin patch that continuously monitors biomarkers in interstitial fluid. This data is analyzed by an AI platform to provide actionable insights for patients and clinicians, enabling earlier detection of health issues and more personalized treatment plans.
**How did
